Myomo, Inc.

One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States

Tel: 617-996-9058
Fax: 617-886-0333

Show jobs for this employer

96 articles with Myomo, Inc.

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2020.

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be presenting at the Sidoti & Company Virtual Microcap Conference on Thursday, November 19, 2020 at 1:45 p.m. Eastern Time. The presentation will be webcast live and av

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun.

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb par

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020 after th

  • Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Harry Kovelman, MD, is joining the Company as its Chief Medical Officer, effective November 2. In this role, Dr

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services under the U.S. Department of Health and Human

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its management is scheduled to present at the H.C. Wainwright 22 nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Paul Gudonis, chief executive officer an

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced additional intellectual property protection with the issuance of new patents in the U.S. and Europe related to MyoPro™, its unique wearable robotic brace for arm and hand paralysis.

  • Myomo, Inc. today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2, 2020 at 11:00 a.m. EDT.

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that a Myomo-trained Orthotic & Prosthetic practice in Australia has received its first insurance authorization to fit a patient with a custom MyoPro device.

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced that it will report financial results for the second quarter ended June 30, 2020 on Monday, August 10, 2020 after the market close.

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced the launch of MyoCare™, a new program that provides enhanced support to first-year users of the Company’s MyoPro® powered brace in order to maximize the benefits they receive from the device.

  • Myomo, Inc. announced that new published research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “Despite long-standing traumatic brain injury, meaningful improvements in motor function were observed.”

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced it has resumed in-person patient visits for casting, fitting and delivering its MyoPro® powered braces in states that are now allowing such interactions.

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported the success of its initiative to conduct safe patient screenings remotely using telehealth technologies.

  • 21% Year-Over-Year Revenue Growth; 51% Sequential Increase in Authorization Backlog

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced that it will report financial results for the first quarter ended March 31, 2020 on Thursday, May 14, 2020 after the market close.

  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported its pipeline of MyoPro candidates continued to grow during the first quarter of 2020, with more than 700 candidates awaiting insurance reimbursement authorization as of March 31, 2020. This compares

  • Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced financial results for the fourth quarter and year ended December 31, 2019.